Ron Laufer, MD.

Ron Laufer, M.D. Senior Managing Director

Ron started his career as a physician and epidemiologist, before moving into venture capital. In 2001, he co-founded Lilly Ventures, the venture capital arm of Eli Lilly & Company. Later he served as a managing director at Visium Asset Management, a healthcare-focused investment firm, before joining MedImmune Ventures in 2010. He is currently or has been a board member of Adheron Therapeutics (acquired by Roche), Armaron Biosciences, Catabasis Pharmaceuticals (NASDAQ: CATB), G1 Therapeutics and VentiRx.

Ron received his B.Sci., M.D. and M.P.H. from Hebrew University, and an M.B.A. from the Harvard Business School.

Samuel Wu, M.D., Ph.D.

Samuel Wu, M.D., Ph.D. Managing Director

Sam joined MedImmune Ventures in 2010 and leads our West Coast office. He is or has been a board member of Applied Genetic Technologies Corp (NASDAQ:AGTC), Cerapedics, and VaxInnate. Previously he was a principal with SV Life Sciences, a healthcare-focused venture capital firm he had joined in 2002, where he invested in a broad range of biopharmaceutical, platform and medical device companies. Before moving into venture capital, he was an Engagement Manager in the Pharmaceuticals and Corporate Finance practices of McKinsey and Company, where he led teams of consultants serving clients on M&A, portfolio analysis and other strategic issues.

Sam holds an A.B. magna cum laude in Biochemistry from Harvard College, attended Stanford University School of Medicine where he earned an M.D. and a Ph.D. in Biochemistry as a Howard Hughes Predoctoral Fellow, and trained in Internal Medicine at the University of California, Los Angeles.